

Invitation to presentation of Q-linea's Interim report Q2-2023 on July 13, 2023

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company's Interim report for the period January – June 2023 on Thursday 13 July 2023, at 07:30 a.m. (CEST).

Q-linea invites to an audiocast with teleconference (in English) or webcast for investors, analysts and media on July 13, 2023, at 13:00-14:00 p.m. (CEST).

Jonas Jarvius, CEO, and Christer Samuelsson, CFO/IR, to present Q-linea and comment on the Interim report followed by a Q&A-session.

If you wish to participate via the webcast, go to the link:

https://ir.financialhearings.com/q-linea-q2-2023

Via the webcast, there is an opportunity to ask written questions.

If you wish to verbally ask questions via conference call, register via the link:

https://conference.financialhearings.com/teleconference/?id=200818

After registration, you will receive a phone number and a conference ID to log into the conference. Via the telephone conference, there is an opportunity to ask questions verbally.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB Jonas.Jarvius@qlinea.com +46 (0) 70-323 77 60

Christer Samuelsson, CFO /IR, Q-linea AB Christer.Samuelsson@qlinea.com +46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.



Attachments

Invitation to presentation of Q-linea's Interim report Q2-2023 on July 13, 2023